VivoSeq
Oncology

Non-Small Cell Lung Cancer (NSCLC)

30

Pipeline Programs↗

17

Active Trials↗

18

Companies Involved↗

Non-small Cell Lung Cancer (NSCLC) is an emerging landscape with 30 programs across 18 companies. The most active players are Pfizer, Kestrel Therapeutics, Inc., Eli Lilly. 14 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

41/100

Mech. Concentration

18/100

Completion Rate

0/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1K

Kestrel Therapeutics, Inc.

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1I

Imclone

1 program

Phase 1Revolution Medicines logo

Revolution Medicines

5 programs

Phase 1Genmab logo

Genmab

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

22 of 28 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody414%Antibody–drug conjugate27%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 91% of 32 pipeline programs.

Analysis

Trial Status

18

clinical trials

Recruiting11 · 61%
Not yet recruiting5 · 28%
Active, not recruiting1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT06694454·60 enrolled
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Recruiting·Revolution Medicines logoRevolution Medicines·Phase 1·NCT07349537·574 enrolled
A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)
Recruiting·Astellas logoAstellas·Phase 3·NCT07566052·356 enrolled
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer
Recruiting·Genmab logoGenmab·Phase 2·NCT07288177·240 enrolled
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06170788·614 enrolled
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07291037·400 enrolled
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Recruiting·Revolution Medicines logoRevolution Medicines·Preclinical·NCT06162221·616 enrolled
A First-in-human Phase 1 Dose-escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
Recruiting·KKestrel Therapeutics, Inc.·Phase 1·NCT07458347·145 enrolled
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT07361497·850 enrolled
A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor
Recruiting·Astellas logoAstellas·Phase 1·NCT07140016·40 enrolled
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT07361510·750 enrolled
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06305754·520 enrolled
A Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccine Alone and in Combination With Toripalimab in Patients With Resected NSCLC
Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT07683832·50 enrolled
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Not yet recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT07680764·160 enrolled
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC: A Multi-center Prospective Study in China
Not yet recruiting·SSun Yat-sen University·N/A·NCT07674524·160 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)